Broad Spectrum Products Against Multiple Neurotoxin Botulinum Serotypes (R61/R33 Clinical Trial Not Allowed)

Due: May 2, 2025

Description

The purpose of this notice of funding opportunity (NOFO) is to support the development of improved products for treating Botulinum Neurotoxin (BoNT) intoxication. Development of products that can reverse BoNT intoxication are highly encouraged. This NOFO will use a milestone-driven, biphasic award mechanism. Transition to the R33 phase will depend on the successful completion of specific milestones during the R61 phase.:

Eligible Applicants- State governments- County governments- City or township governments- Special district governments- Independent school districts- Public and State controlled institutions of higher education- Native American tribal governments (Federally recognized)- Public housing authorities/Indian housing authorities- Native American tribal organizations (other than Federally recognized tribal governments)- Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education- Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education- Private institutions of higher education- For-profit organizations other than small businesses- Small businesses- Others

Additional Eligibility Information

Other Eligible Applicants include the following:

Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-dome...

Funding TypeGrantCategories of Funding Activity- HealthOpportunity TypeDiscretionary

Grantor Contact InformationSee Section VII. Agency Contacts within the full opportunity announcement for all other inquires.Grantor Emailgrantsinfo@nih.govOther Grantor InformaitonNIH Grants Information<br/>grantsinfo@nih.gov

Additional informationhttps://grants.nih.gov/grants/guide/rfa-files/RFA-AI-24-080.htmlSupporting Linkhttp://grants.nih.gov/grants/guide/rfa-files/RFA-AI-24-080.html

Start finding grants with Atom for

$0 today

$30 Billed monthly after 7-day trial. Cancel anytime.

Personalized grant emails delivered weekly, right to your inbox.

AI powered search engine with both keyword and semantic search capabilities.

Grant filters to find the perfect funding opportunities.

Similar Grants

Eligibility

Profile

Finance

Other

Similar Grants

Broad Spectrum Products Against Multiple Neurotoxin Botulinum Serotypes (R61/R33 Clinical Trial Not Allowed)

Start finding grants with Atom for

$0 today

$30 Billed monthly after 7-day trial. Cancel anytime.

Personalized grant emails delivered weekly, right to your inbox.

AI powered search engine with both keyword and semantic search capabilities.

Grant filters to find the perfect funding opportunities.

NCCIH Natural Product Early Phase Clinical Trial Phased Innovation Award (R61/R33 Clinical Trial Required)

NCCIH Natural Product Early Phase Clinical Trial Award (R33 Clinical Trial Required)

Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Neurotherapeutic Agent Characterization and In vivo Efficacy Studies (R61/R33 Clinical Trial Not Allowed)

Broad Spectrum Products Against Multiple Neurotoxin Botulinum Serotypes (R61/R33 Clinical Trial Not Allowed)

Start finding grants with Atom for

$0 today

$30 Billed monthly after 7-day trial. Cancel anytime.

Personalized grant emails delivered weekly, right to your inbox.

AI powered search engine with both keyword and semantic search capabilities.

Grant filters to find the perfect funding opportunities.

NCCIH Natural Product Early Phase Clinical Trial Phased Innovation Award (R61/R33 Clinical Trial Required)

NCCIH Natural Product Early Phase Clinical Trial Award (R33 Clinical Trial Required)

Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Neurotherapeutic Agent Characterization and In vivo Efficacy Studies (R61/R33 Clinical Trial Not Allowed)